Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock market. From the intricate defenses of cybersecurity to the vast frontiers of space technology, and from life-saving biotechnological breakthroughs to the efficiency gains
2 Under-the-Radar Stocks to Buy Heading Into 2026 These drugmakers are poised to profit from their innovative engines.
2 Monster Stocks in the Making There might still be time to get in on the ground floor.
Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss Axsome Therapeutics Q3 2025 results: Revenue beat expectations with strong product sales, but the company reported a wider-than-expected loss.
Pharma Tariffs Back In Spotlight On New Trump Threat President Donald Trump threatened 100% tariffs on some drug imports.
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading Axsome Therapeutics beats Q2 2025 revenue estimates with $150M, driven by Auvelity's 84% YoY growth. Shares rise 6% pre-market on improved EPS.
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028.
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.
Why Is Teva Stock Trading Higher On Tuesday? Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
